Presenter

Wilmer Abdiel Huggins Rivera

Campus

UMass Amherst

Sponsor

Amy Springer, Department of Biochemistry and Molecular Biology, UMass Amherst

Schedule

Session 1, 10:30 AM - 11:15 AM [Schedule by Time][Poster Grid for Time/Location]

Location

Poster Board A75, Campus Center Auditorium, Row 4 (A61-A80) [Poster Location Map]

Abstract

Follicular Lymphoma (FL) is the most common of the non-Hodgkin lymphomas, deemed incurable as existing therapies have proven to be inadequate. Biospecific antibodies (BsAbs), an immuno-therapy that collaborates with the body's immune system to combat the disease, have shown immense promise. However, patient prognosis has shown limitations, with current treatments inducing cytokine release syndrome (CRS) in several patients as physicians are not able to foresee if immune-related adverse events(irAEs) will occur within a patient. To address this gap in predictive technology, our research aims to take a comprehensive approach by meticulously examining immune cell subsets using mass cytometry, also known as mass cytometry by time-of-flight (CyTOF). Employing this advanced technology and gathering patient information through the EPIC software, we anticipate that specific immune markers are key to predicting distinct responses to treatment, such as achieving complete remission and the likelihood of encountering immune-related adverse effects following BsAbs therapy. We conjugated and tested multiple antibodies known to be critical markers for immune cell populations, to be utilized in CyTOF combined with healthy donors to customize the panel to be unique to FL. Additionally, patient profiles sourced from the EPIC software database were analyzed in pursuit of our retrospective cohort's clinical characteristics that may further refine our predictive models. After the extensive conjugating and rigorous testing of antibodies, combined with the pin-point evaluation of patient profiles, we aspire to unveil vital clinical characteristics and biomarkers. This approach may provide invaluable insights that significantly contribute to the BsAbs clinical trials aimed at treating FL.

Keywords

Antibody Conjugation, Cancer Biology, Immune Cell Subsets, Clinical, Bispecific Antibodies

Research Area

Cancer Studies

SIMILAR ABSTRACTS (BY KEYWORD)